This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abrams, T. J. Articles by Cherrington, J. M. Search for Related Content PubMed PubMed Citation Articles by Abrams, T. J. Articles by Cherrington, J. M.

Preclinical Research and Exploratory Development, SUGEN, Inc., South San Francisco, California 94080

¹ To whom requests for reprints should be addressed, at Preclinical Research and Exploratory Development, SUGEN, Inc., 230 East Grand Avenue, South San Francisco, CA 94080. Phone: (650) 837-3655; Fax: (650) 837-3308; E-mail: tinya-abrams{at}sugen.com

The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine kinase KIT in vitro and in vivo, examine the role of KIT in small cell lung cancer (SCLC), and anticipate clinical utility of SU11248 in SCLC. SU11248 is an oral, multitargeted tyrosine kinase inhibitor with direct antitumor and antiangiogenic activity through targeting platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor, KIT, and FLT3 receptors. Treatment of the KIT-expressing SCLC-derived NCI-H526 cell line in vitro with SU11248 resulted in dose-dependent inhibition of stem cell factor-stimulated KIT phosphotyrosine levels and proliferation. The biological significance of KIT inhibition was evaluated in vivo by treating mice bearing s.c. NCI-H526 tumors with SU11248 or another structurally unrelated KIT inhibitor, STI571 (Gleevec), which is also known to inhibit Bcr-Abl and PDGFRß. SU11248 treatment resulted in significant tumor growth inhibition, whereas inhibition from STI571 treatment was less dramatic. Both compounds reduced phospho-KIT levels in NCI-H526 tumors, with a greater reduction by SU11248, correlating with efficacy. Likewise, phospho-PDGFRß levels contributed by tumor stroma and with known involvement in angiogenesis were strongly inhibited by SU11248 and less so by STI571. Because platinum-based chemotherapy is part of the standard of care for SCLC, SU11248 was combined with cisplatin, and significant tumor growth delay was measured compared with either agent alone. These results expand the profile of SU11248 as a KIT signaling inhibitor and suggest that SU11248 may have clinical potential in the treatment of SCLC via direct antitumor activity mediated via KIT as well as tumor angiogenesis via vascular endothelial growth factor receptor FLK1/KDR and PDGFRß.

This article has been cited by other articles:

				M. C. Heinrich, R. G. Maki, C. L. Corless, C. R. Antonescu, A. Harlow, D. Griffith, A. Town, A. Mckinley, W.-B. Ou, J. A. Fletcher, et al. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor J. Clin. Oncol., November 20, 2008; 26(33): 5352 - 5359. [Abstract] [Full Text] [PDF]

				H. van Cruijsen, A. A.M. van der Veldt, L. Vroling, D. Oosterhoff, H. J. Broxterman, R. J. Scheper, G. Giaccone, J. B.A.G. Haanen, A. J.M. van den Eertwegh, E. Boven, et al. Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival Clin. Cancer Res., September 15, 2008; 14(18): 5884 - 5892. [Abstract] [Full Text] [PDF]

				M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410. [Abstract] [Full Text] [PDF]

				P. S. Hodkinson, A. MacKinnon, and T. Sethi Targeting Growth Factors in Lung Cancer Chest, May 1, 2008; 133(5): 1209 - 1216. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr Diseases Desperate Grown J Natl Cancer Inst, April 16, 2008; 100(8): 520 - 521. [Full Text] [PDF]

				H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, et al. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane J. Clin. Oncol., April 10, 2008; 26(11): 1810 - 1816. [Abstract] [Full Text] [PDF]

				Q. Zhou, P. Guo, and J. M. Gallo Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549. [Abstract] [Full Text] [PDF]

				M. A. Socinski, S. Novello, J. R. Brahmer, R. Rosell, J. M. Sanchez, C. P. Belani, R. Govindan, J. N. Atkins, H. H. Gillenwater, C. Pallares, et al. Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2008; 26(4): 650 - 656. [Abstract] [Full Text] [PDF]

				L. B. Saltz, L. S. Rosen, J. L. Marshall, R. J. Belt, H. I. Hurwitz, S. G. Eckhardt, E. K. Bergsland, D. G. Haller, A. C. Lockhart, C. M. Rocha Lima, et al. Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy J. Clin. Oncol., October 20, 2007; 25(30): 4793 - 4799. [Abstract] [Full Text] [PDF]

				D. Mannavola, P. Coco, G. Vannucchi, R. Bertuelli, M. Carletto, P. G. Casali, P. Beck-Peccoz, and L. Fugazzola A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3531 - 3534. [Abstract] [Full Text] [PDF]

				E. Zetterberg, A. M. Vannucchi, A. R. Migliaccio, W. Vainchenker, M. Tulliez, R. Dickie, H. Hasselbalch, R. Rogers, and J. Palmblad Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows Haematologica, May 1, 2007; 92(5): 597 - 604. [Abstract] [Full Text] [PDF]

				G. Giaccone The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970. [Abstract] [Full Text] [PDF]

				L. Q.M. Chow and S. G. Eckhardt Sunitinib: From Rational Design to Clinical Efficacy J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896. [Abstract] [Full Text] [PDF]

				B. I. Rini Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106. [Abstract] [Full Text] [PDF]

				R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma N. Engl. J. Med., January 11, 2007; 356(2): 115 - 124. [Abstract] [Full Text] [PDF]

				S. Patyna, A. D. Laird, D. B. Mendel, A.-M. O'Farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer Ther., July 1, 2006; 5(7): 1774 - 1782. [Abstract] [Full Text] [PDF]

				R. J. Motzer, B. I. Rini, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, J. R. Merchan, G. Wilding, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, June 7, 2006; 295(21): 2516 - 2524. [Abstract] [Full Text] [PDF]

				O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248 Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289. [Abstract] [Full Text] [PDF]

				M. Ciomei, V. Croci, A. Ciavolella, D. Ballinari, and E. Pesenti Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin. Cancer Res., May 1, 2006; 12(9): 2856 - 2861. [Abstract] [Full Text] [PDF]

				H. Prenen, J. Cools, N. Mentens, C. Folens, R. Sciot, P. Schoffski, A. Van Oosterom, P. Marynen, and M. Debiec-Rychter Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate Clin. Cancer Res., April 15, 2006; 12(8): 2622 - 2627. [Abstract] [Full Text] [PDF]

				D. H. Albert, P. Tapang, T. J. Magoc, L. J. Pease, D. R. Reuter, R.-Q. Wei, J. Li, J. Guo, P. F. Bousquet, N. S. Ghoreishi-Haack, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther., April 1, 2006; 5(4): 995 - 1006. [Abstract] [Full Text] [PDF]

				S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, et al. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer J. Clin. Oncol., January 1, 2006; 24(1): 25 - 35. [Abstract] [Full Text] [PDF]

				G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]

				T. A. Carter, L. M. Wodicka, N. P. Shah, A. M. Velasco, M. A. Fabian, D. K. Treiber, Z. V. Milanov, C. E. Atteridge, W. H. Biggs III, P. T. Edeen, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases PNAS, August 2, 2005; 102(31): 11011 - 11016. [Abstract] [Full Text] [PDF]

				K. Pietras and D. Hanahan A Multitargeted, Metronomic, and Maximum-Tolerated Dose "Chemo-Switch" Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer J. Clin. Oncol., February 10, 2005; 23(5): 939 - 952. [Abstract] [Full Text] [PDF]

				M. von Mehren Targeted Therapy With Imatinib: Hits and Misses? J. Clin. Oncol., January 1, 2005; 23(1): 8 - 10. [Full Text] [PDF]

				E. Tamborini, L. Bonadiman, T. Negri, A. Greco, S. Staurengo, P. Bidoli, U. Pastorino, M. A. Pierotti, and S. Pilotti Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8214 - 8219. [Abstract] [Full Text] [PDF]

				J. A. Cain, J. L. Grisolano, A. D. Laird, and M. H. Tomasson Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657 Blood, July 15, 2004; 104(2): 561 - 564. [Abstract] [Full Text] [PDF]

				J. Matsui, T. Wakabayashi, M. Asada, K. Yoshimatsu, and M. Okada Stem Cell Factor/c-kit Signaling Promotes the Survival, Migration, and Capillary Tube Formation of Human Umbilical Vein Endothelial Cells J. Biol. Chem., April 30, 2004; 279(18): 18600 - 18607. [Abstract] [Full Text] [PDF]

				E. Tamborini, L. Bonadiman, A. Greco, A. Gronchi, C. Riva, R. Bertulli, P. G. Casali, M. A. Pierotti, and S. Pilotti Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor {beta} Tyrosine Kinase Receptors in Synovial Sarcoma Clin. Cancer Res., February 1, 2004; 10(3): 938 - 943. [Abstract] [Full Text] [PDF]

				M. C. Heinrich Is KIT an Important Therapeutic Target in Small Cell Lung Cancer?: Commentary re: B. E. Johnson et al., Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin. Cancer Res., 9: 5880-5887, 2003. Clin. Cancer Res., December 1, 2003; 9(16): 5825 - 5828. [Full Text] [PDF]

				N. K. Pryer, L. B. Lee, R. Zadovaskaya, X. Yu, J. Sukbuntherng, J. M. Cherrington, and C. A. London Proof of Target for SU11654: Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors Clin. Cancer Res., November 15, 2003; 9(15): 5729 - 5734. [Abstract] [Full Text] [PDF]

				K. G. Moss, G. C. Toner, J. M. Cherrington, D. B. Mendel, and A. D. Laird Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 476 - 480. [Abstract] [Full Text] [PDF]

				W. G. Kaelin Jr. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2703 - 2711. [Abstract] [Full Text] [PDF]

				T. J. Abrams, L. J. Murray, E. Pesenti, V. Walker Holway, T. Colombo, L. B. Lee, J. M. Cherrington, and N. K. Pryer Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer Mol. Cancer Ther., October 1, 2003; 2(10): 1011 - 1021. [Abstract] [Full Text]